Annual report pursuant to Section 13 and 15(d)

Segment Information - Schedule of Segment Information (Details)

v3.20.4
Segment Information - Schedule of Segment Information (Details) - USD ($)
12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Net Loss $ (10,092,363) $ (11,818,652)
Total operating costs and expenses 9,978,202 12,140,005
Less non-cash share-based compensation (4,137,460) (5,713,746)
Operating costs and expenses excluding non-cash share-based compensation 5,840,742 6,426,259
Total assets 9,452,964 6,293,693
CAR-T Therapeutics [Member]    
Net Loss (2,241,443) (5,074,868)
Operating costs and expenses excluding non-cash share-based compensation 1,141,542 2,212,090
Total assets 2,988,124 2,382,460
Cancer Vaccines [Member]    
Net Loss (828,136) (677,450)
Operating costs and expenses excluding non-cash share-based compensation 365,681 458,392
Total assets 946,923 489,881
Anti-Viral Therapeutics [Member]    
Net Loss (1,168,969)
Operating costs and expenses excluding non-cash share-based compensation 739,140
Total assets 2,464,361
Cancer Diagnostics [Member]    
Net Loss (5,836,594) (5,196,471)
Operating costs and expenses excluding non-cash share-based compensation 3,581,377 2,689,761
Total assets 2,869,529 2,921,784
Patent Licensing [Member]    
Net Loss (17,221) (869,863)
Operating costs and expenses excluding non-cash share-based compensation 13,002 1,066,016
Total assets $ 184,027 $ 499,568